Healthcare Industry News: embolic protection
News Release - October 18, 2006
Genesis Medical Interventional to Launch F.A.S.T.(TM) Funnel Catheter(TM) at Upcoming TCT Meeting October 23 in Washington, DC.
REDWOOD CITY, Calif.--(HSMN NewsFeed)--Genesis Medical Interventional, Inc. proudly announces the commercialization of the novel F.A.S.T. Funnel Catheter Proximal Occlusion and Thrombectomy Device at the Cardiovascular Research Foundation's (CRF) eighteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., October 22-27, 2006. The F.A.S.T. Funnel Catheter provides temporary occlusion proximal to a vascular lesion with an innovative funnel that allows the physician to perform Focused Aspiration(TM), directing maximum aspirative force and dramatically enhancing the efficiency of removal of thrombus or emboli. The F.A.S.T. Funnel Catheter, the essence of "elegant simplicity," will initially target coronary, SVG, and distal peripheral interventions.Dr. Mark Webster, of Auckland, NZ, will present the results of a multi-institutional clinical trial utilizing the F.A.S.T Funnel Catheter for Proximal Occlusion embolic protection on Tuesday morning, October 24, and during the Innovative New Technologies session, Thursday, October 26, 2006. In addition to the participants of the trial, Genesis has received the enthusiastic and overwhelming responses and endorsements of prominent cardiologists and interventionalists because of the effectiveness and ease of use of the device.
Genesis will be exhibiting the F.A.S.T Funnel Catheter at booth number 251 in the Emerging Technologies Area of the TCT Exhibit Hall, and will provide a "wet lab" demonstrating the instant on/off occlusion feature, intuitive ease of use, the innovative funnel, and other features of the device. A complete description of the F.A.S.T Funnel Catheter can be found at http://www.genesismedical.net/html/products.html or at www.genesismedical.net.
The company, which was awarded the prestigious Medical Design Excellence Award in 2005, has targeted a total overall market for its products of well over $1B. The F.A.S.T. Funnel Catheter is Genesis' first commercially available device from a stable of devices in the development/regulatory pipeline that also includes devices for intracranial, carotid, coronary, and peripheral intervention as well as one for dialysis graft/fistula management. Will Dubrul, CEO of Genesis, states, "Because of the elegant simplicity of the F.A.S.T. Funnel Catheter design, Genesis Medical is poised to make a significant impact in the huge thrombectomy market currently and in the even larger thrombectomy and embolic protection markets once other products come on line."
About Genesis Medical Interventional, Inc.
Genesis Medical Interventional, Inc. (Genesis) is a privately held company developing products, based on its minimally invasive Funnel Catheter platform technologies, to remove thrombi and emboli from the vasculature. The company believes its technologies will have applications in many major medical markets. The F.A.S.T. Funnel Catheter has been cleared by the FDA via 510(k) marketing clearance and has a proven track record with over 100 peripheral and coronary clinical cases completed with excellent results.
For additional information, please contact William R. Dubrul, Genesis CEO at will@genesismedical.net or visit the Genesis website at www.genesismedical.net.
This press release contains forward-looking statements that are based upon management's current expectations and are inherently uncertain. Forward-looking statements are based upon information available to us as of the date of this press release and we assume no obligation to revise or update any such forward-looking statement to reflect any event or circumstance after the date of this release. Actual results and timing of events could differ materially from current expectations and from any forward-looking statements made by the company.
Source: Genesis Medical Interventional
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
